Medikamentöse Adipositastherapie in Deutschland

Incretin-based medications such as liraglutide, semaglutide, and tirzepatide may improve weight reduction and cardiometabolic health in people with obesity.

• Obesity treatment typically starts with a conservative multimodal approach, including a low-energy diet and increased physical activity.
• If initial treatment goals are not met, pharmacotherapy may support ongoing management of obesity.
• Incretin-based drugs have shown benefits beyond weight loss, including improvements in conditions like type 2 diabetes and hypertension.
• These medications are associated with mild to moderate gastrointestinal side effects.
• Setmelanotide has been launched for the treatment of rare monogenic obesity forms.
• Several new incretin-based agents and different drug classes are in advanced clinical development, potentially enhancing obesity pharmacotherapy.

AI simplified